Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 17/2023

23-11-2023 | Filgrastim | AdisInsight Report

Motixafortide: First Approval

Author: Sheridan M. Hoy

Published in: Drugs | Issue 17/2023

Login to get access

Abstract

Motixafortide (APHEXDATM) is a selective C-X-C motif chemokine receptor 4 (CXCR4) inhibitor being developed by BioLineRx under licence from Biokine Therapeutics for the mobilization of haematopoietic stem cells (HSCs) and the treatment of various cancers. On 11 September 2023, motixafortide was approved in the USA for use in combination with filgrastim [granulocyte colony stimulating factor (G-CSF)] to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Motixafortide has been granted Orphan Drug Designation for the treatment of pancreatic cancer in the EU and the USA, and for the treatment of acute myeloid leukaemia in the USA. Clinical development is ongoing for the mobilization of CD34+ HSCs for gene therapy in patients with sickle cell disease. This article summarizes the milestones in the development of motixafortide leading to this first approval.
Appendix
Available only for authorised users
Literature
1.
Parrondo RD, Ailawadhi S, Sher T, et al. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020;16(2):56–66.CrossRefPubMed
2.
Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308.CrossRefPubMed
3.
Crees ZD, Rettig MP, DiPersio JF. Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Ther Adv Hematol. 2023;14:1–13.CrossRef
4.
Crees ZD, Rettig MP, Jayasinghe RG, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023;29(4):869–79.CrossRefPubMedPubMedCentral
5.
Ladikou EE, Chevassut T, Pepper CJ, et al. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Br J Haematol. 2020;189(5):815–25.CrossRefPubMed
6.
Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011;39(3):282–92.CrossRefPubMed
7.
8.
BioLineRx Ltd. BioLineRx announces FDA approval of APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma [media release]. 11 Sep 2023. https://​biolinerx.​com/​.
9.
BioLineRx Ltd. BioLineRx receives Orphan Drug Designation for motixafortide (BL-8040) for the treatment of pancreatic cancer in Europe [media release]. 14 Jan 2020. http://​www.​biolinerx.​com.
10.
BioLineRx Ltd. BioLineRx receives Orphan Drug Designation from the FDA for its lead therapeutic candidate BL-8040 for the treatment of pancreatic cancer [media release]. 4 Feb 2019. http://​www.​biolinerx.​com.
11.
12.
13.
14.
BioLineRx Ltd. BioLineRx in-licenses a novel, phase II ready drug for the treatment of leukemia and other hematological cancers [media release]. 4 Sep 2012. http://​www.​biolinerx.​com.
15.
BioLineRx Ltd. BioLineRx announces collaboration with MSD to investigate the combination of KEYTRUDA (pembrolizumab) and BL-8040 in pancreatic cancer [media release]. 12 Jan 2016. https://​biolinerx.​com/​.
16.
17.
BioLineRx Ltd. BioLineRx signs second clinical immuno-oncology collaboration agreement to investigate combination of BL-8040 and KEYTRUDA® for pancreatic cancer [media release]. 8 Aug 2016. http://​www.​biolinerx.​com.
18.
BioLineRx Ltd. BioLineRx announces clinical research collaboration to investigate combination of BL-8040 with atezolizumab in multiple oncology indications [media release]. 7 Sept 2016. http://​www.​biolinerx.​com.
19.
20.
BioLineRx Ltd. BioLineRx announces collaboration agreement with GenFleet Therapeutics to further develop motixafortide in pancreatic ductal adenocarcinoma (PDAC) [media release]. 28 June 2022. http://​www.​genfleet.​com.
21.
BioLineRx Ltd. BioLineRx announces clinical trial collaboration with Washington University School of Medicine to evaluate motixafortide for CD34+ hematopoietic stem cell mobilization for gene therapies in sickle cell disease [media release]. 6 Mar 2023. http://​www.​biolinerx.​com.
22.
BioLineRx Ltd. BioLineRx increases stake in BL-8040, its lead oncology platform in late stage development for multiple oncology indications [media release]. 3 Oct 2018. http://​www.​biolinerx.​com.
23.
24.
25.
26.
Rebolledo-Bustillo M, Garcia-Gomez D, Dávila EM, et al. Structural basis of the binding mode of the antineoplastic compound motixafortide (BL-8040) in the CXCR4 chemokine receptor. Int J Mol Sci. 2023;24(5):1–14.CrossRef
27.
Abraham M, Biyder K, Begin M, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells. 2007;25(9):2158–66.CrossRefPubMed
28.
Abraham M, Pereg Y, Bulvik B, et al. Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34(+) cells in healthy volunteers. Clin Cancer Res. 2017;23(22):6790–801.CrossRefPubMed
29.
Crees ZD, Rettig MP, Bashey A, et al. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. Blood Adv. 2023;7(18):5210–4.CrossRefPubMedPubMedCentral
30.
Xia J, Jotte MRM, Sun S, et al. The CXCR4 antagonist, BL8040, is highly active against human T-ALL in preclinical models [abstract]. Blood. 2018;132(Suppl 1).
31.
Crees ZD, Stockerl-Goldstein K, Vainstein A, et al. GENESIS: a phase III randomized double-blind, placebo-controlled, multi-center trial evaluating the safety and efficacy of BL-8040 and G-CSF in mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma. Lead-in period results [abstract no. 455]. Biol Blood Marrow Transplant. 2019;25(3):S308–9.CrossRef
32.
Lamotte M, DiPersio JF, Siegel DS, et al. Cost-effectiveness analysis of motixafortide on top of G-CSF for stem cell mobilization for autologous bone marrow transplantation in patients with multiple myeloma [abstract no. EE56]. Value Health. 2022;25(Suppl 7):S346.CrossRef
33.
Lamotte M, DiPersio JF, Siegel D, et al. Cost-effectiveness analysis of motixafortide versus plerixafor in stem cell mobilization for autologous transplantation in patients with multiple myeloma [abstract]. Blood. 2022;140(Suppl 1):10794–5.CrossRef
34.
Crees ZD, Stockerl-Goldstein K, Vainstein A, et al. GENESIS: phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. Future Oncol. 2019;15(31):3555–63.CrossRefPubMedPubMedCentral
35.
Peled A, Abraham M, Avivi I, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20(2):469–79.CrossRefPubMed
36.
Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878–85.CrossRefPubMed
37.
Bockorny B, Macarulla T, Semenisty V, et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial. Clin Cancer Res. 2021;27(18):5020–7.CrossRefPubMed
38.
Borthakur G, Ofran Y, Tallman MS, et al. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study. Cancer. 2021;127(8):1246–59.CrossRefPubMed
39.
Segura SJ, Wass M, Schaffrath J, et al. Double-blind, placebo controlled, randomized, multicenter, phase II study to assess the efficacy of the high affinity CXCR4 inhibitor BL-8040 as addition to consolidation therapy in AML by the SAL and OSHO Leukemia Study Groups [abstract no. 1446]. Blood. 2022;140(Suppl 1):3338–40.CrossRef
Metadata
Title
Motixafortide: First Approval
Author
Sheridan M. Hoy
Publication date
23-11-2023
Publisher
Springer International Publishing
Published in
Drugs / Issue 17/2023
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-023-01962-w

Other articles of this Issue 17/2023

Drugs 17/2023 Go to the issue

AdisInsight Report

Elranatamab: First Approval

AdisInsight Report

Sunvozertinib: First Approval

Review Article

Current Medical Therapy for Adenomyosis: From Bench to Bedside

Adis Drug Evaluation

Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults

Current Opinion

The Place of Cannabinoids in the Treatment of Gynecological Pain

Leading Article

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis